Eli Lilly Launches Direct-to-Consumer Sales of Zepbound for Weight Loss

Direct-to-Consumer Sales:
Eli Lilly has announced that it will sell Zepbound, a weight loss medication, directly to consumers through its LillyDirect platform, bypassing traditional insurance coverage.

Affordable Pricing:
The medication will be available in single-dose vials at a significantly lower price than the auto-injector pens, with a one-month supply costing $349 for a 2.5-milligram dose and $549 for a 5-milligram dose.

No Insurance Coverage:
This new option is self-pay only and does not participate in insurance, making it more accessible to individuals without coverage.

Educational Resources:
Consumers purchasing Zepbound through LillyDirect will have access to educational resources on how to administer the medication.

Counterfeit Protection:
By selling directly to consumers, Eli Lilly aims to protect patients from counterfeit or unsafe versions of the medication.

Clinical Benefits:
Zepbound has been shown to help patients lose between 5% and 20% of their body weight over time, but it requires a prescription and should be used in conjunction with diet and exercise.